US Patent Issued to JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG on Nov. 18 for "GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers" (Swiss, German Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,354, issued on Nov. 18, was assigned to JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG (Wurzburg, Germany).

"GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers" was invented by Jorg Wischhusen (Wurzburg, Germany), Markus Haake (Estenfeld, Germany), Reinhard Dummer (Zurich, Switzerland) and Matthias Mehling (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability ...